Soluble urokinase receptor is released selectively by glioblastoma cells that express epidermal growth factor receptor variant III and promotes tumor cell migration and invasion

Journal of Biological Chemistry

Volumn 290, Issue 24, 2015, Pages 14798-14809

  Gilder, Andrew S ^a   Jones, Karra A ^a   Hu, Jingjing ^a   Wang, Lei ^a   Chen, Clark C ^a   Carter, Bob S ^a   Gonias, Steven L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOASSAY; CELLS; CYTOLOGY; GENE EXPRESSION; GENES; MAMMALS; MOBILE SECURITY; SIGNALING; TUMORS;

CONDITIONED MEDIUM; CONSTITUTIVELY ACTIVES; EPIDERMAL GROWTH FACTOR RECEPTORS; GENE AMPLIFICATION; GLIOBLASTOMA CELLS; NEUTRALIZING ANTIBODIES; PLASMA SAMPLES; TUMOR CELL MIGRATION;

CELL SIGNALING;

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ARTICLE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME RELEASE; GENE EXPRESSION; GENE SILENCING; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PARACRINE SIGNALING; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; BRAIN TUMOR; GLIOBLASTOMA; METABOLISM; METASTASIS; PATHOLOGY; POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL LINE; TUMOR INVASION; XENOGRAFT;

MUS;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; GLIOBLASTOMA; HETEROGRAFTS; HUMANS; MICE; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR;

EID: 84931291979     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.637488     Document Type: Article

References (63)

1. Smith, H. W., and Marshall, C. J. (2010) Regulation of cell signalling by uPAR. Nat. Rev. Mol. Cell Biol. 11, 23-36
2. Collen, D. (1999) The plasminogen (fibrinolytic) system. Thromb. Haemost. 82, 259-270
3. Liu, D., Aguirre Ghiso, J., Estrada, Y., and Ossowski, L. (2002) EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1, 445-457
4. Wei, Y., Lukashev, M., Simon, D. I., Bodary, S. C., Rosenberg, S., Doyle, M. V., and Chapman, H. A. (1996) Regulation of integrin function by the urokinase receptor. Science 273, 1551-1555
5. Tarui, T., Mazar, A. P., Cines, D. B., and Takada, Y. (2001) Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J. Biol. Chem. 276, 3983-3990
6. Resnati, M., Pallavicini, I., Wang, J. M., Oppenheim, J., Serhan, C. N., Romano, M., and Blasi, F. (2002) The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc. Natl. Acad. Sci. U. S. A. 99, 1359-1364
7. Blasi, F., and Carmeliet, P. (2002) uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 3, 932-943
8. Solberg, H., Ploug, M., Høyer-Hansen, G., Nielsen, B. S., and Lund, L. R. (2001) The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling. J. Histochem. Cytochem. 49, 237-246
9. Plesner, T., Ralfkiaer, E., Wittrup, M., Johnsen, H., Pyke, C., Pedersen, T. L., Hansen, N. E., Danø, K. (1994) Expression of the receptor for urokinasetype plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am. J. Clin. Pathol. 102, 835-841
10. Mandriota, S. J., Seghezzi, G., Vassalli, J. D., Ferrara, N., Wasi, S., Mazzieri, R., Mignatti, P., and Pepper, M. S. (1995) Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J. Biol. Chem. 270, 9709-9716
11. Reidy, M. A., Irvin, C., and Lindner, V. (1996) Migration of arterial wall cells: expression of plasminogen activators and inhibitors in injured rat arteries. Circ. Res. 78, 405-414
12. Shetty, S., Kumar, A., Johnson, A. R., Pueblitz, S., Holiday, D., Raghu, G., and Idell, S. (1996) Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs. Am. J. Respir. Cell Mol. Biol. 15, 78-87
13. Holst-Hansen, C., Hamers, M. J., Johannessen, B. E., Brünner, N., and Stephens, R. W. (1999) Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies. Br. J. Cancer 81, 203-211
14. Savva, A., Raftogiannis, M., Baziaka, F., Routsi, C., Antonopoulou, A., Koutoukas, P., Tsaganos, T., Kotanidou, A., Apostolidou, E., Giamarellos-Bourboulis, E. J., and Dimopoulos, G. (2011) Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilatorassociated pneumonia and sepsis. J. Infect. 63, 344-350
15. Sidenius, N., Sier, C. F., Ullum, H., Pedersen, B. K., Lepri, A. C., Blasi, F., and Eugen-Olsen, J. (2000) Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 96, 4091-4095
16. Koga, T., Okada, A., Kawashiri, S., Kita, J., Suzuki, T., Nakashima, Y., Tamai, M., Satoh, K., Origuchi, T., Iwamoto, N., Yamasaki, S., Nakamura, H., Migita, K., Ida, H., Ueki, Y., et al. (2011) Soluble urokinase plasminogen activator receptor as a useful biomarker to predict the response to adalimumab in patients with rheumatoid arthritis in a Japanese population. Clin. Exp. Rheumatol. 29, 811-815
17. Zimmermann, H. W., Koch, A., Seidler, S., Trautwein, C., and Tacke, F. (2012) Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver Int. 32, 500-509
18. Edsfeldt, A., Nitulescu, M., Grufman, H., Grönberg, C., Persson, A., Nilsson, M., Persson, M., Björkbacka, H., and Gonçalves, I. (2012) Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque. Stroke 43, 3305-3312
19. Rigolin, G. M., Tieghi, A., Ciccone, M., Bragotti, L. Z., Cavazzini, F., Della Porta, M., Castagnari, B., Carroccia, R., Guerra, G., Cuneo, A., and Castoldi, G. (2003) Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extrabone marrow involvement in multiple myeloma patients. Br. J. Haematol. 120, 953-959
20. Shariat, S. F., Roehrborn, C. G., McConnell, J. D., Park, S., Alam, N., Wheeler, T. M., and Slawin, K. M. (2007) Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J. Clin. Oncol. 25, 349-355
21. Henic, E., Borgfeldt, C., Christensen, I. J., Casslén, B., and Høyer-Hansen, G. (2008) Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin. Cancer Res. 14, 5785-5793
22. Lomholt, A. F., Christensen, I. J., Høyer-Hansen, G., and Nielsen, H. J. (2010) Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. Acta Oncol. 49, 805-811
23. Langkilde, A., Hansen, T. W., Ladelund, S., Linneberg, A., Andersen, O., Haugaard, S. B., Jeppesen, J., and Eugen-Olsen, J. (2011) Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancerfree individuals. Cancer Epidemiol. Biomarkers Prev. 20, 609-618
24. Jing, J., Zheng, S., Han, C., Du, L., Guo, Y., and Wang, P. (2012) Evaluating the value of uPAR of serum and tissue on patients with cervical cancer. J. Clin. Lab. Anal. 26, 16-21
25. Almasi, C. E., Brasso, K., Iversen, P., Pappot, H., Høyer-Hansen, G., Danø, K., and Christensen, I. J. (2011) Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer. Prostate 71, 899-907
26. Riisbro, R., Christensen, I. J., Piironen, T., Greenall, M., Larsen, B., Stephens, R. W., Han, C., Høyer-Hansen, G., Smith, K., Brünner, N., and Harris, A. L. (2002) Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of T. Clin. Cancer Res. 8, 1132-1141
27. Jo, M., Thomas, K. S., Wu, L., and Gonias, S. L. (2003) Soluble urokinasetype plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling. J. Biol. Chem. 278, 46692-46698
28. Rao, J. S., Gujrati, M., and Chetty, C. (2013) Tumor-associated soluble uPAR-directed endothelial cell motility and tumor angiogenesis. Oncogenesis 2, e53
29. Sidenius, N., Sier, C. F., and Blasi, F. (2000) Shedding and cleavage of the urokinase receptor (uPAR): Shedding and cleavage of uPA: identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett. 475, 52-56
30. Mazzieri, R., D'Alessio, S., Kenmoe, R. K., Ossowski, L., and Blasi, F. (2006) An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration. Mol. Biol. Cell 17, 367-378
31. Selleri, C., Montuori, N., Ricci, P., Visconte, V., Carriero, M. V., Sidenius, N., Serio, B., Blasi, F., Rotoli, B., Rossi, G., and Ragno, P. (2005) Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood 105, 2198-2205
32. Wei, C., El Hindi, S., Li, J., Fornoni, A., Goes, N., Sageshima, J., Maiguel, D., Karumanchi, S. A., Yap, H.-K., Saleem, M., Zhang, Q., Nikolic, B., Chaudhuri, A., Daftarian, P., Salido, E., et al. (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat. Med. 17, 952-960
33. Harada, K., Nishizaki, T., Ozaki, S., Kubota, H., Ito, H., and Sasaki, K. (1998) Intratumoral cytogenetic heterogeneity detected by comparative genomic hybridization and laser scanning cytometry in human gliomas. Cancer Res. 58, 4694-4700
34. Brennan, C. W., Verhaak, R. G., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., Beroukhim, R., Bernard, B., Wu, C.-J., Genovese, G., Shmulevich, I., et al. (2013) The somatic genomic landscape of glioblastoma. Cell 155, 462-477
35. Bonavia, R., Inda, M.-M., Cavenee, W. K., and Furnari, F. B. (2011) Heterogeneity maintenance in glioblastoma: a social network. Cancer Res. 71, 4055-4060
36. Gill, B. J., Pisapia, D. J., Malone, H. R., Goldstein, H., Lei, L., Sonabend, A., Yun, J., Samanamud, J., Sims, J. S., Banu, M., Dovas, A., Teich, A. F., Sheth, S. A., McKhann, G. M., Sisti, M. B., et al. (2014) MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proc. Natl. Acad. Sci. 111, 12550-12555
37. Sanai, N., Alvarez-Buylla, A., and Berger, M. S. (2005) Neural stem cells and the origin of gliomas. N. Engl. J. Med. 353, 811-822
38. Libermann, T. A., Razon, N., Bartal, A. D., Yarden, Y., Schlessinger, J., and Soreq, H. (1984) Expression of epidermal growth factor receptors in human brain tumors expression of epidermal growth factor receptors in human brain tumors. Cancer Res. 44, 753-760
39. Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., and Schlessinger, J. (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313, 144-147
40. Huang, H. S., Nagane, M., Klingbeil, C. K., Lin, H., Nishikawa, R., Ji, X.-D., Huang, C. M., Gill, G. N., Wiley, H. S., Cavenee, W. K., and Su Huang, H. J. (1997) The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J. Biol. Chem. 272, 2927-2935
41. Inda, M.-M., Bonavia, R., Mukasa, A., Narita, Y., Sah, D. W., Vandenberg, S., Brennan, C., Johns, T. G., Bachoo, R., Hadwiger, P., Tan, P., Depinho, R. A., Cavenee, W., and Furnari, F. (2010) Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 24, 1731-1745
42. Hu, J., Jo, M., Cavenee, W. K., Furnari, F., VandenBerg, S. R., and Gonias, S. L. (2011) Cross-talk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proc. Natl. Acad. Sci. 108, 15984-15989
43. Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., and Huang, H. J. (1994) Amutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. U. S. A. 91, 7727-7731
44. Mukasa, A., Wykosky, J., Ligon, K. L., Chin, L., Cavenee, W. K., and Furnari, F. (2010) Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc. Natl. Acad. Sci. U. S. A. 107, 2616-2621
45. Ekstrand, A. J., Longo, N., Hamid, M. L., Olson, J. J., Liu, L., Collins, V. P., and James, C. D. (1994) Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene. Oncogene 9, 2313-2320
46. Gonias, S. L., Gaultier, A., and Jo, M. (2011) Regulation of the urokinase receptor (uPAR) by LDL receptor-related protein-1 (LRP1). Curr. Pharm. Des. 17, 1962-1969
47. Salkeni, M. A., Zarzour, A., Ansay, T. Y., McPherson, C. M., Warnick, R. E., Rixe, O., and Bahassiel, M. (2013) Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients. J. Neurooncol. 115, 27-35
48. Jo, M., Thomas, K. S., Marozkina, N., Amin, T. J., Silva, C. M., Parsons, S. J., and Gonias, S. L. (2005) Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator. J. Biol. Chem. 280, 17449-17457
49. Jo, M., Thomas, K. S., Takimoto, S., Gaultier, A., Hsieh, E. H., Lester, R. D., and Gonias, S. L. (2007) Urokinase receptor primes cells to proliferate in response to epidermal growth factor. Oncogene 26, 2585-2594
50. Hu, J., Muller, K. A., Furnari, F. B., Cavenee, W. K., VandenBerg, S. R., and Gonias, S. L. (2014) Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling. Oncogene 10.1038/onc.2014.336
51. Shinojima, N., Tada, K., Shiraishi, S., Kamiryo, T., Kochi, M., Nakamura, H., Makino, K., Saya, H., Hirano, H., Kuratsu, J., Oka, K., Ishimaru, Y., and Ushio, Y. (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 63, 6962-6970
52. Chumbalkar, V., Latha, K., Hwang, Y., Maywald, R., Hawley, L., Sawaya, R., Diao, L., Baggerly, K., Cavenee, W. K., Furnari, F. B., and Bogler, O. (2011) Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of Δ EGFR. J. Proteome Res. 10, 1343-1352
53. Wykosky, J., Hu, J., Gomez, G. G., Taylor, T., Villa, G. R., Pizzo, D., VandenBerg, S. R., Thorne, A. H., Chen, C. C., Mischel, P. S., Gonias, S. L., Cavenee, W. K., and Furnari, F. B. (2015) A urokinase receptor-bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer Res. 75, 394-404
54. Francis, J. M., Zhang, C.-Z., Maire, C. L., Jung, J., Manzo, V. E., Adalsteinsson, V. A., Homer, H., Haidar, S., Blumenstiel, B., Pedamallu, C. S., Ligon, A. H., Love, J. C., Meyerson, M., and Ligon, K. L. (2014) EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 4, 956-971
55. Wilhelm, O. G., Wilhelm, S., Escott, G. M., Lutz, V., Magdolen, V., Schmitt, M., Rifkin, D. B., Wilson, E. L., Graeff, H., and Brunner, G. (1999) Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J. Cell. Physiol. 180, 225-235
56. Pyke, C., Eriksen, J., Solberg, H., Nielsen, B. S., Kristensen, P., Lund, L. R., and Danø, K. (1993) An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator. FEBS Lett. 326, 69-74
57. Bruntz, R. C., Taylor, H. E., Lindsley, C. W., and Brown, H. A. (2014) Phospholipase D2 mediates survival signaling through direct regulation of Akt in glioblastoma cells. J. Biol. Chem. 289, 600-616
58. Scott, S. A., Selvy, P. E., Buck, J. R., Cho, H. P., Criswell, T. L., Thomas, A. L., Armstrong, M. D., Arteaga, C. L., and Lindsley, C. W. (2009) Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat. Chem. Biol. 5, 108-117
59. Degryse, B., Resnati, M., Czekay, R.-P., Loskutoff, D. J., and Blasi, F. (2005) Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor. J. Biol. Chem. 280, 24792-24803
60. Montuori, N., Carriero, M. V., Salzano, S., Rossi, G., and Ragno, P. (2002) The cleavage of the urokinase receptor regulates its multiple functions. J. Biol. Chem. 277, 46932-46939
61. Montuori, N., and Ragno, P. (2009) Multiple activities of a multifaceted receptor: roles of cleaved and soluble upar. Front. Biosci. 14, 2494-2503
62. Fazioli, F., Resnati, M., Sidenius, N., Higashimoto, Y., Appella, E., and Blasi, F. (1997) A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 16, 7279-7286
63. Resnati, M., Guttinger, M., Valcamonica, S., Sidenius, N., Blasi, F., and Fazioli, F. (1996) Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 15, 1572-1582